Evidence of increased exposure to Toxoplasma gondii in individuals with recent onset psychosis but not with established schizophrenia

PLoS Neglected Tropical Diseases

Volumn 11, Issue 11, 2017, Pages

  Yolken, Robert ^a   Torrey, E Fuller ^b   Dickerson, Faith ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanley Medical Research Institute   (United States)

^c SHEPPARD PRATT HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PROTOZOON ANTIBODY;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; NONHUMAN; PSYCHOSIS; SCHIZOPHRENIA; SEROLOGY; TOXOPLASMA GONDII; ADOLESCENT; AGED; ANIMAL; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; TOXOPLASMA; TOXOPLASMOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, PROTOZOAN; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TOXOPLASMA; TOXOPLASMOSIS; YOUNG ADULT;

EID: 85036632450     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0006040     Document Type: Article

References (30)

1. Sinai AP, Watts EA, Dhara A, Murphy RD, Gentry MS, Patwardhan A, Reexamining Chronic Toxoplasma gondii Infection: Surprising Activity for a "Dormant" Parasite. Curr Clin Microbiol Rep. 2016;3(4):175–85. doi: 10.1007/s40588-016-0045-3 28191447; PubMed Central PMCID: PMCPMC5295825.
2. Kijlstra A, Petersen E, Epidemiology, pathophysiology, and the future of ocular toxoplasmosis. Ocul Immunol Inflamm. 2014;22(2):138–47. doi: 10.3109/09273948.2013.823214 24131274.
3. Torrey EF, Yolken RH, Schizophrenia and Infections: The Eyes Have It. Schizophr Bull. 2017;43(2):247–52. doi: 10.1093/schbul/sbw113 27507268.
4. Mortensen PB, Norgaard-Pedersen B, Waltoft BL, Sorensen TL, Hougaard D, Yolken RH, Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull. 2007;33(3):741–4. doi: 10.1093/schbul/sbm009 17329231; PubMed Central PMCID: PMCPMC2526131.
5. Hamdani N, Daban-Huard C, Lajnef M, Richard JR, Delavest M, Godin O, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148(2–3):444–8. doi: 10.1016/j.jad.2012.11.034 23273549.
6. Zhang Y, Traskman-Bendz L, Janelidze S, Langenberg P, Saleh A, Constantine N, et al. Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. J Clin Psychiatry. 2012;73(8):1069–76. doi: 10.4088/JCP.11m07532 22938818.
7. Markovitz AA, Simanek AM, Yolken RH, Galea S, Koenen KC, Chen S, et al. Toxoplasma gondii and anxiety disorders in a community-based sample. Brain Behav Immun. 2015;43:192–7. doi: 10.1016/j.bbi.2014.08.001 25124709.
8. Nimgaonkar VL, Yolken RH, Wang T, Chang CC, McClain L, McDade E, et al. Temporal Cognitive Decline Associated With Exposure to Infectious Agents in a Population-based, Aging Cohort. Alzheimer Dis Assoc Disord. 2016;30(3):216–22. doi: 10.1097/WAD.0000000000000133 26710257; PubMed Central PMCID: PMCPMC4919236.
9. Kozar Z, Studies on toxoplasmosis in mental diseases]. Biul Panstw Inst Med Morsk Trop J W Gdansku. 1953;5:134–7; English transl. 13182565.
10. Torrey EF, Bartko JJ, Yolken RH, Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull. 2012;38(3):642–7. doi: 10.1093/schbul/sbs043 22446566; PubMed Central PMCID: PMCPMC3329973.
11. Sugden K, Moffitt TE, Pinto L, Poulton R, Williams BS, Caspi A, Is Toxoplasma Gondii Infection Related to Brain and Behavior Impairments in Humans? Evidence from a Population-Representative Birth Cohort. PLoS One. 2016;11(2):e0148435. doi: 10.1371/journal.pone.0148435 26886853; PubMed Central PMCID: PMCPMC4757034.
12. de Witte LD, van Mierlo HC, Litjens M, Klein HC, Bahn S, Osterhaus AD, et al. The association between antibodies to neurotropic pathogens and schizophrenia: a case-control study. NPJ Schizophr. 2015;1:15041. doi: 10.1038/npjschz.2015.41 27336045; PubMed Central PMCID: PMCPMC4849462.
13. Avramopoulos D, Pearce BD, McGrath J, Wolyniec P, Wang R, Eckart N, et al. Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. PLoS One. 2015;10(3):e0116696. doi: 10.1371/journal.pone.0116696 25781172; PubMed Central PMCID: PMCPMC4363491.
14. Sutterland AL, Fond G, Kuin A, Koeter MW, Lutter R, van Gool T, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand. 2015;132(3):161–79. doi: 10.1111/acps.12423 25877655.
15. Fond G, Macgregor A, Tamouza R, Hamdani N, Meary A, Leboyer M, et al. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci. 2014;264(2):179–83. doi: 10.1007/s00406-013-0413-4 23771405.
16. Jones-Brando L, Torrey EF, Yolken R, Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003;62(3):237–44. 12837520.
17. Dickerson F, Adamos MB, Katsafanas E, Khushalani S, Origoni A, Savage CLG, et al. The association among smoking, HSV-1 exposure, and cognitive functioning in schizophrenia, bipolar disorder, and non-psychiatric controls. Schizophr Res. 2016;176(2–3):566–71. doi: 10.1016/j.schres.2016.05.022 27262384.
18. Dickerson F, Boronow J, Stallings C, Origoni A, Yolken R, Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality. Schizophr Bull. 2007;33(3):737–40. doi: 10.1093/schbul/sbm005 17314085; PubMed Central PMCID: PMCPMC2526149.
19. Dickerson F, Schroeder J, Stallings C, Origoni A, Katsafanas E, Schwienfurth LA, et al. A longitudinal study of cognitive functioning in schizophrenia: clinical and biological predictors. Schizophr Res. 2014;156(2–3):248–53. doi: 10.1016/j.schres.2014.04.019 24827555.
20. First MB, User's guide for the structured clinical interview for DSM-IV axis II personality disorders: SCID-II. Washington, DC: American Psychiatric Press; 1997. 91 p. p.
21. Randolph C, Tierney MC, Mohr E, Chase TN, The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310–9. doi: 10.1076/jcen.20.3.310.823 9845158.
22. Overall JE, Beller SA, The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol. 1984;39(2):187–93. 6699374.
23. Torrey EF, Bartko JJ, Lun ZR, Yolken RH, Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(3):729–36. doi: 10.1093/schbul/sbl050 17085743; PubMed Central PMCID: PMCPMC2526143.
24. Rougier S, Montoya JG, Peyron F, Lifelong Persistence of Toxoplasma Cysts: A Questionable Dogma?: (Trends in Parasitology 33, 93–101; 2017). Trends Parasitol. 2017;33(5):414. doi: 10.1016/j.pt.2017.02.001 28236522.
25. Konishi E, Annual change in immunoglobulin G and M antibody levels to Toxoplasma gondii in human sera. Microbiol Immunol. 1989;33(5):403–11. 2755363.
26. Yuksel P, Kocazeybek B, Ozdemir A, Yolken RH, Torrey EF, Stability of Toxoplasma gondii: Antibody levels in schizophrenia. Schizophr Res. 2017. doi: 10.1016/j.schres.2017.02.009 28256300.
27. Dubey JP, Hill DE, Jones JL, Hightower AW, Kirkland E, Roberts JM, et al. Prevalence of viable Toxoplasma gondii in beef, chicken, and pork from retail meat stores in the United States: risk assessment to consumers. J Parasitol. 2005;91(5):1082–93. doi: 10.1645/GE-683.1 16419752.
28. Alday PH, Bruzual I, Nilsen A, Pou S, Winter R, Ben Mamoun C, et al. Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii. Antimicrob Agents Chemother. 2017;61(2). doi: 10.1128/AAC.01866-16 27919897; PubMed Central PMCID: PMCPMC5278733.
29. Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, et al. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci U S A. 2012;109(39):15936–41. doi: 10.1073/pnas.1208069109 23019377; PubMed Central PMCID: PMCPMC3465437.
30. Liu Z, Yin L, Li Y, Yuan F, Zhang X, Ma J, et al. Intranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice. BMC Immunol. 2016;17(1):37. doi: 10.1186/s12865-016-0173-9 27716047; PubMed Central PMCID: PMCPMC5053087.